A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 3932-3939

  Doyle, Patricia S ^a,b   Zhou, Yuan M ^a   Engel, Juan C ^a   McKerrow, James H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; CRUZIPAIN; CYSTEINE PROTEINASE INHIBITOR; K 11777; NIFURTIMOX; RECOMBINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; FEMALE; HEART; HISTOPATHOLOGY; IMMUNE DEFICIENCY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; SPLEEN; TRYPANOSOMA CRUZI;

ANIMALS; CATTLE; CELLS, CULTURED; CHAGAS DISEASE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; NIFURTIMOX; NITROIMIDAZOLES; PROTOZOAN PROTEINS; SURVIVAL ANALYSIS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 35848971033     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00436-07     Document Type: Article

References (34)

1. Abdulla, M. H., K. C. Lim, M. Sajid, J. H. McKerrow, and C. R. Caffrey. 2007. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med. 4:e14.
2. Altcheh, J., M. Biancardi, A. Lapena, G. Ballering, and H. Freilij. 2005. Congenital Chagas disease: experience in the Hospital de Niños, Ricardo Gutierrez, Buenos Aires, Argentina. Rev. Soc. Bras. Med. Trop. 38:41-45.
3. Aparicio, J. M., J. Scharfstein, and A. P. Lima. 2004. A new cruzipain-mediated pathway of human cell invasion by Trypanosoma cruzi requires trypomastigote membranes. Infect. Immun. 72:5892-5902.
4. Avila, H., A. M. Goncalves, N. S. Nehme, C. M. Morel, and L. Simpson. 1990. Schizodeme analysis of Trypanosoma cruzi stocks from South and Central America by analysis of PCR-amplified minicircle variable region sequences. Mol. Biochem. Parasitol. 42:175-188.
5. Barcán, L., C. Lunaó, L. Clara, A. Sinagra, A. Valledor, A. M. De Rissio, A. Gadanoá, M. García, E. Santibañes, and A. A. Riarte. 2005. Transmission of T. cruzi infection via liver transplantation to a nonreactive recipient for Chagas' disease. Liver Transplant. 11:1112-1116.
6. Castro, J. A., M. M. de Meca, and L. C. Bartel. 2006. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Human Exp. Toxicol. 25:471-479.
7. CDC. 2001. Chagas' disease after organ transplantation - United States. Morb. Mortal. Wkly. Rep. 51:210-212.
8. Chagas, C. 1982. Coletanea de trabalhos cientificos, 1909-1913, p. 11-79, 237-335. Editora Universidade de Brasilia, Brasilia, Brazil.
9. Chimelli, L., and F. Scaravilli. 1997. Trypanosomiasis. Brain Pathol. 7:599-611.
10. Corti, M., and C. Yampolski. 2006. Prolonged survival and immune reconstitution after chagasic meningoencephalitis in a patient with acquired immunodeficiency syndrome. Rev. Soc. Bras. Med. Trop. 39:85-88.
11. De Andrade, A. L., F. Zicker, R. M. de Oliveira, S. Almeida-Sitva, A. Luquetti, L. R. Travassos, I. C. Almeida, S. S. de Andrade, J. G. de Andrade, and C. M. Martelli. 1996. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348:1407-1413.
12. Doyle, P. S., J. A. Dvorak, and J. C. Engel. 1984. Trypanosoma cruzi: quantification and analysis of the infectivity of cloned stocks. J. Protozool. 31:280.
13. Du, X., C. Guo, E. Hansell, P. S. Doyle, C. R. Caffrey, T. P. Holler, J. H. McKerrow, and F. E. Cohen. 2002. Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem. 45:2695-2707.
14. Engel, J. C., J. A. Dvorak, E. L. Segura, and M. St. J. Crane. 1982. Trypanosoma cruzi: biological characterization of 19 clones derived from two chagasic patients. Growth kinetics in liquid medium. J. Protozool. 29:550-560.
15. Engel, J. C., P. S. Doyle, J. Palmer, D. F. Bainton, and J. H. McKerrow. 1998. Cysteine protease inhibitors alter Golgi complex structure and function in Trypanosoma cruzi J. Cell Sci. 111:597-606.
16. Engel, J. C., P. S. Doyle, I. Hsieh, and J. H. McKerrow. 1998. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 188:725-734.
17. Engel, J. C., P. S. Doyle, and J. H. McKerrow. 1999. Trypanocidal effect of cysteine protease inhibitors in vitro and in vivo in experimental Chagas' disease. Medicina (Buenos Aires) 59:171-175.
18. Estani, S. S., E. L. Segura, A. M. Ruiz, E. Velazquez, B. M. Porcel, and C. Yampotis. 1998. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am. J. Trop. Med. Hyg. 59:526-529.
19. Estani, S. S., and E. L. Segura. 1999. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina. Mem. Inst. Oswaldo Cruz 94:363-365.
20. Ferreira, M. S. 1999. Chagas' disease and immunosuppression. Mem. Inst. Oswaldo Cruz 94:325-327.
21. Gallerano, R. R., and R. R. Sosa. 2000. Interventional study in the natural evolution of Chagas' disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy. Rev. Fac. Cien. Med. Univ. Nac. Cordoba 57:135-162.
22. Izadjoo, M. J., Y. Polotsky, M. G. Mense, A. K. Bhattacharjee, C. M. Paranavitana, T. L. Hadfield, and D. L. Hoover. 2000. Impaired control of Brucella melitensis infection in Rag1-deficient mice. Infect. Immun. 68:5314-5320.
23. Jurado, J., E. Alejandre-Duran, and C. Pueyo. 1993. Genetic differences between the standard Ames tester strains TA100 and TA98. Mutagenesis 8:527-532.
24. Kaneshima, E. N., and M. A. A. Castro-Prado. 2005. Benznidazole-induced genotoxicity in diploid cells of Aspergillus nidulans. Mem. Inst. Oswaldo Cruz 100:325-330.
25. Moraga, A. A., and U. Graf. 1989. Genotoxicity testing of antiparasitic nitrofurans in the Drosophila wing somatic mutation and recombination test. Mutagenesis 4:105-110.
26. Palmer, J. T., D. Rasnick, J. L. Klaus, and D. Bromme. 1995. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 38:3193-3196.
27. Raether, W., and H. Hånel. 2003. Nitroheterocyclic drugs with broad-spectrum activity. Parasitol. Res. 90:S19-S39.
28. Solomon, S. L. 14 May 2003. CDC response to infections related to human tissue transplantation. www.senate.gov/~govt-aff/051403solomon.pdf.
29. Tarleton, R. L., and L. Zhang. 1999. Chagas' disease etiology: autoimmunity or parasite persistence? Parasitol. Today 15:94-99.
30. Texeira, A. R. L., N. Nitz, M. C. Guimarao, C. Gomes, and C. A. Santos-Buch. 2006. Review: Chagas' disease. Postgrad. Med. J. 82:788-798.
31. Tomas, A. M., M. A. Miles, and J. M. Kelly. 1997. Overexpression of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, is associated with enhanced metacyclogenesis. Eur. J. Biochem. 244:596-603.
32. Viotti, R., C. Vigliano, B. Lococo, G. Bertocchi, M. Pett, M. G. Alvarez, M. Postan, and A. Armenti. 2006. Long-term cardiac outcomes of treating chronic Chagas' disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med. 144:724-734.
33. Young, C., P. Losikoff, A. Chawla, L. Glasser, and E. Forman. 2007. Transfusion complications: transfusion-acquired Trypanosoma cruzi infection. Transfusion 47:54.
34. Zhang, L, and R. L. Tarleton. 1999. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J. Infect. Dis. 180:480-486.